Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.
Zehua WangJianwen GaoYuko OhnoHaiou LiuCong-Jian XuPublished in: Cancer chemotherapy and pharmacology (2020)
Rosiglitazone combined with olaparib can help manage ovarian cancer by ameliorating olaparib-induced senescence and improving anti-tumor effects.